News | May 31, 2021
Sun Pharmaceutical’s internals remain strong: ICICI Securities
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
This marks Glenmark's first synthetic decapeptide injectable approval
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Subscribe To Our Newsletter & Stay Updated
